Company: ARWR
Filing Date: 2025-01-29
Form Type: ARS
Source: 0001628280-25-002866
Chunk: 217

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-01-29
Form: ARS
Chunk 217
---
 vested in the year $ 48,337 $ 849,095 $ 4,696 $ 334,881 $ — $ 186,244 $ — $ (188,531) Compensation Actually Paid $ (5,232,848) $ 2,614,573 $ (2,160,939) $ 2,298,902 $ (40,073,641) $ (386,118) $ 69,061,855 $ 6,080,786 * Amounts presented are averages for the entire group of Other NEOs in each respective year. (3) Total Shareholder Return (TSR) is calculated by dividing (a) the sum of (i) the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and (ii) the difference between the Company’s share price at the end of each fiscal year shown and the beginning of the measurement period, and the beginning of the measurement period by (b) the Company’s share price at the beginning of the measurement period. The beginning of the measurement period for each year in the table is September 30, 2020. (4) The peer group used for this purpose is the Nasdaq Biotechnology Index. (5) The dollar amounts reported represent the amount of net income reflected in the Company’s audited financial statements for the applicable year. (6) The Company does not use any financial performance measures to link executive compensation actually paid to company performance. Consequently, no “Company Selected Measure” is included in the table above. Analysis of Information Presented in the Pay versus Performance Table As described in more detail in the Compensation Discussion and Analysis section, the Company’s executive compensation program reflects a variable pay-for- performance philosophy. While the Company utilizes several performance measures to align executive compensation with Company performance, all of those Company measures are not presented in the Pay versus Performance table. Moreover, the Company generally seeks to incentivize long-term performance, and therefore does not specifically align the Company’s performance measures with compensation that is actually paid (as computed in accordance with SEC rules) for a particular year. In accordance with SEC rules, the Company is providing the following descriptions of the relationships between information presented in the Pay versus Performance table. Table of Contents 2025 PROXY STATEMENT 54

Compensation Actually Paid, Cumulative TSR and Peer Group TSR To ta l S ha re ho ld er R et ur n (G ro w th o f $ 10 0 in ve st ed ) C A P ($ M ill